Nazione: Regno Unito
Lingua: inglese
Fonte: MHRA (Medicines & Healthcare Products Regulatory Agency)
Etoricoxib
Teva UK Ltd
M01AH05
Etoricoxib
30mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 10010100; GTIN: 5017007027577
TEVA UK Ref:
231-30-32574-B LEA ETORICOXIB 30MG, 60MG, 90MG AND 120MG FC TABS TUK
Leggi il documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Etoricoxib 30 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 30 mg of etoricoxib. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablets Blue, round biconvex film-coated tablet, debossed "30" on one side and plain on the other, approx. 6 mm diameter. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. Etoricoxib is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1). _ _ _Osteoarthritis _ The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. _ _ _Rheumatoid arthritis_ The recommended dose is 90 mg once daily. _ _ _Ankylosing spondylitis _ The recommended dose is 90 mg once daily. For acute pain conditions, etoricoxib should be used only for the acute symptomatic period. _Acute gouty arthritis_ The recommended dose is 120 mg once daily. In clinical trials for acute gout Leggi il documento completo